louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05427877: Safety of Pulsing Heating Device Use on the Skin
Official title: Safety of Pulsing Heating Device Use on the Skin
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain
Lead sponsor: Integrative Skin Science and Research
Sponsor class: INDUSTRY
Collaborators: name: Soovu Labs Inc.
First posted: 2022-06-22
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: We hope to assess the safety of a recurrent heating device for pain relief.


Eligibility criteria: Inclusion Criteria:

* Individuals in good general health.
* No known medical conditions that, in the investigator's opinion, may interfere with study participation.
* Subjects 18 year of age and older.

Exclusion Criteria:

* Individuals who have history of acute or chronic disease that would likely interfere with or increase the risk on study participation at the discretion of the investigator.
* Individuals with peripheral neuropathy or a neuropathic condition that would alter their ability to sense pain.
* Individuals with clinically significant unstable medical disorders that would disqualify the participant at the discretion of the investigator.
* Individuals who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study at the discretion of the investigator.
* Women who are pregnant.

Primary outcomes:
measure: Pain - Visual Analog Scale
timeFrame: 100 minutes
measure: Erythema (skin redness)
timeFrame: 100 minutes
measure: Post-inflammatory hyperpigmentation
timeFrame: 100 minutes
Secondary outcomes:
measure: Mood and Anxiety Assessment
timeFrame: 100 minutes
measure: Mood and Anxiety Assessment
timeFrame: 1 week
measure: Pain - Visual Analog Scale
timeFrame: 1 week
measure: Erythema (skin redness)
timeFrame: 1 week
measure: Post-inflammatory hyperpigmentation
timeFrame: 1 week
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: Integrative Skin Science and Research
state: California
Study officials:
References:
Clinical trial NCT06755177: Clinical Features and Visual Prognosis of Infectious Endophthalmitis
Official title: Be Cautious of the Endogenous Endophthalmitis--Clinical Characteristics and Visual Prognosis of 104 Cases of Infectious Endophthalmitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endophthalmitis
Keywords: Infectious endophthalmitis
Endogenous endophthalmitis
Exogenous endophthalmitis
Lead sponsor: Zhongnan Hospital
Sponsor class: OTHER
First posted: 2025-01-01
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All inhabitants

Brief summary: The aim of this observational study was to retrospectively examine the clinical data of patients with infectious endophthalmitis and to analyse their clinical characteristics.

The main question it aims to answer is: to find the differences between endogenous and exogenous endophthalmitis and to provide new ideas for the diagnosis and treatment of infectious endophthalmitis.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with infectious endophthalmitis by specialist examination. The clinical diagnosis of endophthalmitis was established on the basis of clinical signs and symptoms, including ocular pain, loss of vision, eyelid oedema, conjunctival congestion, inflammation of the anterior chamber (flare-ups, cells, pupillary fibrin membranes, and pus accumulation in the anterior chamber), vitritis, and vitreous clouding on B-scan ultrasound. The diagnosis of infectious endophthalmitis was clarified by the aqueous vitreous pathogen detection test.

Exclusion Criteria:

* Patients with incomplete medical records; non-infectious uveitis, retinal tumour disease, ocular ischaemia syndrome and other diseases with similar manifestations to endophthalmitis.

Primary outcomes:
measure: visual acuity
timeFrame: Pre-operative, post-operative follow-up at 1 month, 3 months, 1 year, etc.
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT04714177: Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
Official title: Efficacy and Safety of Edaravone Dexborneol in Addition to Standard of Care in Patients With Hypertensive Intracerebral Hemorrhage: a Randomized, Double-Blind, Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Intracerebral Hemorrhage
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
Collaborators: name: Jiangsu Simcere Pharmaceutical Co., Ltd.
First posted: 2021-01-19
Enrollment: 390
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: pending


Eligibility criteria: Inclusion Criteria:

* Written informed consent from the patient or legally acceptable representative
* Males and females
* Diagnose as hypertensive intracerebral hemorrhage
* Onset of symptoms within 6\~48 hours
* Position of bleeding major in basal ganglia
* The sum of scores on items 5 and 6 on the NIHSS were \>= 2 at baseline and the total score (items 1-11) was \>=6 and \<=20
* Volume of Hematoma \<= 30 ml
* Premorbid mRS score of 0 or 1

Exclusion Criteria:

* Allergy to known study drugs or excipients
* Experienced stroke in latest 3 month
* Volume of Hematoma \> 5 ml in other bleeding position
* Obstructive hydrocephalus
* Any diagnosis as other than hypertensive ICH
* Unconsciousness
* Severe concurrent illness with life expectancy less than 90 days
* Pregnancy or breast-feeding

Primary outcomes:
measure: The proportionof Participants With modified Rankin Scale (mRS) 0 ~ 1
timeFrame: 90 days after the first dose of study treatment
Secondary outcomes:
measure: The proportion of death
timeFrame: 90 days after the first dose of study treatment
measure: The proportionof Participants With modified Rankin Scale (mRS)
timeFrame: 14, 30 and 90 days after the first dose of study treatment
measure: The change in the NIH stroke scale (NIHSS) from the baseline
timeFrame: 14, 30 and 90 days after the first dose of study treatment
measure: The proportionof Participants With Glasgow Outcome Score (GOS)
timeFrame: 14, 30 and 90 days after the first dose of study treatment
measure: Barthel Index (BI)
timeFrame: 90 days after the first dose of study treatment
measure: Stroke Specific Quality of Life Scale (SS-QOL)
timeFrame: 90 days after the first dose of study treatment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05390177: Memory for Health Research Findings
Official title: Memory for Health Research Findings
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Healthy Aging
Lead sponsor: University of Colorado, Colorado Springs
Sponsor class: OTHER
First posted: 2022-05-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Participants from two age groups (young vs. older adults) will be compared for two experimental conditions. Although age group cannot be randomly assigned, the comparison between groups makes the design factorial.
Primary purpose: BASIC_SCIENCE

Brief summary: This experiment tests young (ages 18-35) and older adult (ages 60-80) participants. Participants will watch a brief video, will complete a memory task, and will complete measures about their beliefs.

Detailed description: Participants (360 young adults and 360 older adults) will complete a baseline beliefs measure and will then be randomly assigned to one of two study conditions. They will watch a 2.5-min video that presents research findings related to their health. Their memory for the video will be tested, and participants will also complete a demographic questionnaire and another survey about their beliefs. Participation will last 15-20 minutes.

Eligibility criteria: Inclusion Criteria:

* 18 to 35 years old or 60 to 80 years old
* Fluent English speakers

Exclusion Criteria:

-

Primary outcomes:
measure: Health Beliefs
timeFrame: 3 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Colorado Springs
country: United States
facility: UCCS
state: Colorado
Study officials:
affiliation: University of Colorado, Colorado Springs
name: Lori James, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05534477: Verily Clinical Study Watch Analytical Validation Study
Official title: Verily Clinical Study Watch Analytical Validation Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Healthy Population
Chronic Disease
Lead sponsor: Verily Life Sciences LLC
Sponsor class: INDUSTRY
First posted: 2022-09-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Up to 100 participants will be enrolled. This is a decentralized study across the United States.

Brief summary: This study is designed to evaluate the performance of the Verily Clinical Study Watch for the quantification of participants' movement and pulse rate when the wearer is at rest.


Eligibility criteria: Inclusion Criteria:

* Participant is ≥ 22 and ≤ 80 years old
* Participant understands the study requirements and is able and willing to provide written informed consent
* Participant is without significant limitation in ability to participate in the study, in the opinion of the investigator
* Participant owns a smartphone with a data plan and be the primary user of the smartphone; smartphone must be compatible with the applications used in the study
* Participant is a US Resident

Exclusion Criteria:

* Participant has tremor or significant life-threatening arrhythmia
* Participant is allergic to nickel or metal jewelry
* Participant has a known severe allergy to polyester, nylon, or spandex
* Participant has a known allergic reaction to adhesives or hydrogels
* Participant has a tattoo covering the area where the watch face would rest on either wrist
* Participant has planned international travel during the study

Primary outcomes:
measure: Accuracy of pulse rate when wearer is at rest
timeFrame: Approximately 14-day at-home observational period with two virtual visits, one at the beginning and the other at the end of the at-home period.
measure: Sensitivity of movement detection
timeFrame: Approximately 14-day at-home observational period with two virtual visits, one at the beginning and the other at the end of the at-home period.
measure: Specificity of movement detection
timeFrame: Approximately 14-day at-home observational period with two virtual visits, one at the beginning and the other at the end of the at-home period.
Secondary outcomes:
Other outcomes:
Locations:
city: South San Francisco
country: United States
facility: Verily Life Sciences
state: California
Study officials:
affiliation: Verily Life Sciences
name: Scooter Plowman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00083577: Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
Official title: UARK 98-003, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
Thalidomide
Anti-Angiogenesis
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2004-05-27
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.

Detailed description: Patients will receive thalidomide in the oral form (by mouth). Then the dose of thalidomide will be increased each week until week 7 as long as there are no significant side effects. After week 7, patients will continue to receive thalidomide as long as there is no toxicity requiring the treatment to be stopped and as long as there is no evidence of rapid tumor growth during the treatment with thalidomide.

Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered, if any, and provide the available treatments for side effects accordingly. Blood tests will be done once a month for the first six months of receiving thalidomide.

Eligibility criteria: Inclusion Criteria:

* All patients must have a confirmed diagnosis of previously treated, active multiple myeloma
* Myeloma protein should be evident from which to evaluate response
* Must be 18 years of age or older. Women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
* Patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
* Patients must have a total white blood cell count of 2,000 K/microliters. Patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
* Patients must have adequate liver function as demonstrated by a direct bilirubin of \< or = 2.0 mg/dL.

Exclusion Criteria:

* Patients must not have an active infection requiring parenteral antibiotics
* No other concurrent therapy for myeloma is permitted while on Thalidomide

Primary outcomes:
measure: To determine tumor response, overall and progression free survival following thalidomide therapy in patients with multiple myeloma
Secondary outcomes:
measure: To determine toxicities associated with thalidomide in patients with multiple myeloma
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences/MIRT
state: Arkansas
Study officials:
affiliation: UAMS
name: Bart Barlogie, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00845377: Changing Minds - Supporting Depressed Elderly People With an Individually Tailored Service Model
Official title: Changing Minds - Studying the Effects of a Tailored Psychosocial Support Model on Depressive Mood and Quality of Life in Depressive Elderly People
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Depression
Psychological Well-Being
Keywords: Depression
Aging
Psychological well-being
Psychosocial intervention
Lead sponsor: Central Union for the Welfare of the Aged
Sponsor class: OTHER
Collaborators: name: University of Eastern Finland
First posted: 2009-02-18
Enrollment: 200
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Depression is one of the leading causes of emotional suffering in later life. It has been estimated that 2-5% of community-dwelling elderly people suffer from major depression, but according to recent studies, as much as 25 % have clinically significant depressive symptoms.Typically, depressive symptoms in the elderly are treated solely with antidepressants.

The aim of this project is to study the effects of a comprehensive psychosocial intervention on the psychological well-being, quality of life and use of services in depressed elderly people. In addition, the processes of intervention are studied from the perspective of the participants as well as the service system. The research is conducted in collaboration with the city of Espoo. The design of the study combines clinical trial with qualitative process analysis.


Eligibility criteria: Inclusion Criteria:

* age 60+

Exclusion Criteria:

* severe memory disease

Primary outcomes:
measure: Alleviating depressive symptoms measured with Geriatric Depression Scale
timeFrame: base line, 6 months, 1 year
Secondary outcomes:
measure: Quality of life measured with WHO QuolBref
timeFrame: base line, 6 months, 1 year
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Central Union for the Welfare of the Aged
Study officials:
affiliation: Central Union for the Welfare of the Aged
name: Marja K Saarenheimo, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04755777: Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill
Official title: Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill: a Multicenter Mixed-methods Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Critical Illness
Keywords: pharmacokinetics
therapeutic drug monitoring
mixed methods
implementation science
beta-lactam antibiotic
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-02-16
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data will be obtained from ICU clinicians at three hospitals with distinct beta-lactam dosing and monitoring practices: Royal Brisbane and Women's Hospital in Queensland Australia, University of Florida Health Shands Hospital, Gainesville, Florida, United States, and the Mayo Clinic Hospital in Rochester, Minnesota, United States. The sampling frame will include key clinician stakeholders likely to be involved with beta-lactam TDM in the intensive care unit (i.e., pharmacists, intensivists, infectious diseases experts, medical/surgical trainees, and advanced practice providers).

Brief summary: The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.


Eligibility criteria: Inclusion Criteria:

* Providers involved with beta-lactam TDM for critically ill patients

Exclusion Criteria:

* None

Primary outcomes:
measure: Frequency of drug level testing recommended
timeFrame: Baseline
measure: Nature of drug level testing recommended
timeFrame: Baseline
Secondary outcomes:
measure: Determinants of beta-lactam TDM implementation
timeFrame: Baseline
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: UF Health Shands
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Herston
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
Study officials:
affiliation: Mayo Clinic
name: Erin Barreto, Pharm. D.,R.Ph.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ausman S, Boehmer K, et al. Open Forum Infectious Diseases. 2022;9(Supplement 2):ofac492.034.
citation: Barreto EF, Rule AD, Alshaer MH, Roberts JA, Abdul Aziz MH, Scheetz MH, Mara KC, Jannetto PJ, Gajic O, O'Horo JC, Boehmer KR. Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. Implement Sci Commun. 2021 Mar 24;2(1):34. doi: 10.1186/s43058-021-00134-9.
Clinical trial NCT01070277: Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Diarrhea
Abdominal Pain
Bloating
Keywords: chronic diarrhea
travelers
Parasites
albendazole
tinidazole
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-02-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study hypotheses is that Antiparasitic therapy in patients with chronic diarrhea after travel to a developing country, with a negative stool findings, will be significantly effective in eliminating diarrhea and other gastro-intestinal complaints compared to similar patients receiving placebo.

Detailed description: It is common to encounter travelers from developing countries who suffer from persistent diarrhea after returning home. In many cases repeated stool samples are negative for bacteria, parasites and helminthes and the cause of the diarrhea is not found.

The main debate is whether this condition is a persistent parasitic infection (unidentified) or post-infectious irritable bowel syndrome.However, clinical experience suggests that some of these travelers respond to antiparasitic therapy.

This study aims to answer the question whether antiparasitic treatment in these cases is beneficial.

Eligibility criteria: Inclusion Criteria:

* Diarrhea (3 or more soft stools per day) for at least two weeks after a trip to a developing country in the past year
* Stool sample negative for bacteria, parasites and helminthes at least once
* Has not received, until now, antiparasitic or antihelminthic therapy

Exclusion Criteria:

* Bloody diarrhea
* Fever during enrolment 5. Allergy to the offered medication

Primary outcomes:
measure: improvement in gastrointestinal complaints
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ramat Gan
country: Israel
facility: Chaim Sheba Medical Center, Tel Hashomer, Israel
city: Ramat-Gan
country: Israel
facility: Sheba Medical Center
Study officials:
References:
Clinical trial NCT04766853: Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
Official title: Verification of the Efficacy / Safety of the Intratympanic Drug Delivery Vehicle for Treating Intractable Hearing Loss (pilot Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hearing Loss, Sudden
Hearing Loss, Ototoxic
Hearing Loss, Noise-Induced
Meniere Disease
Keywords: Hearing loss
Drug Delivery
Dexamethasone
Hyaluronic Acid
Intratympanic injection
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 15
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a prospective, randomized pilot study. To verify an efficacy and safety of the Intratympanic drug delivery vehicle, patients who have not responded to the existing standard treatment will be enrolled. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.


Eligibility criteria: Inclusion Criteria:

* Sudden hearing loss, ototoxic hearing loss, noise-induced hearing loss, meniere's disease patients with 25dB HL in pure tone audiometry
* Patients whose hearing has not been restored after standard treatment
* Patients do not participate in clinical trials within 6 months

Exclusion Criteria:

* Patients with retrocochlear lesion
* Patients with history of hypersensitivity to the ingredients of this drug
* Patients with end-stage renal disease, end-stage liver disease, cardiovascular surgery, progressive brain tumor, progressive palsy and progressive stroke, etc. severe brain disease or cancer.

Primary outcomes:
measure: Verification of tympanic membrane with endoscopy (Safety)
timeFrame: 3-4 weeks after intratympanic injection
measure: Confirmation of inflammation and drug with CT imaging (Durability)
timeFrame: 1 day and/or 1 weeks after intratympanic injection
measure: Valuation of hearing threshold with Pure tone audiometry (Efficacy)
timeFrame: 3-4 weeks after intratympanic injection
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References: